7 min

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment‪?‬ GRACEcast Lung Cancer Video

    • Science

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

  • Copyright 2013 GRACE - All Rights Reserved

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

7 min

  • Copyright 2013 GRACE - All Rights Reserved

Top Podcasts In Science

NASA's Curious Universe
NASA's Curious Universe
National Aeronautics and Space Administration (NASA)
Living Planet
Living Planet
DW
All About Radiotherapy
All About Radiotherapy
Cancer Research UK Cambridge Centre
Overheard at National Geographic
Overheard at National Geographic
National Geographic
The Session with Tom Swarbrick
The Session with Tom Swarbrick
Global
Science Weekly
Science Weekly
The Guardian

More by GRACEcast

GRACEcast Cancer 101 Video
GRACEcast Cancer 101 Video
cancerGRACE - H. Jack West, MD
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Head and Neck Cancer Video NEW
cancerGRACE - H. Jack West, MD
GRACEcast Bladder Cancer Video
GRACEcast Bladder Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Cancer 101 Audio
GRACEcast Cancer 101 Audio
cancerGRACE - H. Jack West, MD
GRACEcast Kidney Cancer Video
GRACEcast Kidney Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Pancreatic Cancer Video
GRACEcast Pancreatic Cancer Video
cancerGRACE - H. Jack West, MD